Shunt performance in 349 patients with hydrocephalus after aneurysmal subarachnoid hemorrhage

Joona Tervonen1,2 · Hadie Adams1 · Antti Lindgren1,2 · Antti-Pekka Elomaa1 · Olli-Pekka Kämäräinen1,2 · Virve Kärkkäinen1 · Mikael von und zu Fraunberg1,2 · Jukka Huttunen1,2 · Timo Koivisto1,2 · Juha E. Jääskeläinen1,2 · Ville Leinonen1,2 · Terhi J. Huuskonen1,2

Received: 12 January 2021 / Accepted: 9 May 2021 / Published online: 24 June 2021
© The Author(s) 2021

Abstract
Background Shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage (aSAH) is a common sequelae leading to poorer neurological outcomes and predisposing to various complications.
Methods A total of 2191 consecutive patients with aSAH were acutely admitted to the Neurointensive Care at the Kuopio University Hospital between 1990 and 2018 from a defined population. A total of 349 (16%) aSAH patients received a ventriculoperitoneal shunt, 101 with an adjustable valve (2012–2018), 232 with a fixed pressure valve (1990–2011), and 16 a valveless shunt (2010–2013). Clinical timelines were reconstructed from the hospital records and nationwide registries until death (n = 120) or June 2019.
Results Comparing the adjustable valves vs. the fixed pressure valves vs. the valveless shunts, intraventricular hemorrhage was present in 61%, 44% and 100%, respectively. The median times to the shunt were 7 days vs. 38 days vs. 10 days. The rates of the first revision were 25% vs. 32% vs. 69%. The causes included infection in 11% vs. 7% vs. 25% and overdrainage in 1% vs. 4% vs. 31%. The valveless shunt was the only independent risk factor (HR 2.9) for revision. After the first revision, more revisions were required in 48% vs. 52% vs. 45%.
Conclusions The protocol to shunt evolved over time to favor earlier shunt. In post-aSAH hydrocephalus, adjustable valve shunts, without anti-siphon device, can be installed at an early phase after aSAH, in spite of intraventricular blood, with a modest risk (25%) of revision. Valveless shunts are not recommendable due to high risk of revisions.

Keywords Aneurysmal subarachnoid hemorrhage · Hydrocephalus · Critical care · Prognosis · Shunting · Revisions

Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) is the third most common form of stroke (7 per 100,000)[12] at the lowest median age [21, 31, 35]. Acute aSAH is a complex systemic condition, requiring acute CT diagnosis and neurointensive care [7, 9, 31, 34]. Arterial bleed may cause an intracerebral (ICH) and/or intraventricular hematoma (IVH). Age, clinical condition, ICH, IVH, acute hydrocephalus, and extraventricular drainage (EVD) predict high mortality at 14 days [17], excess mortality at 12 months [19], and subsequent neurological outcome [13, 14, 16, 29].

Chronic hydrocephalus, requiring a permanent shunt, is frequent among aSAH survivors [1, 8, 36]. In our 1551 aSAH patients, six groups were identified with increasing risk (1% to 61%) of shunting [1]. Acute hydrocephalus, with or without IVH, predicted that EVD would be continued by a shunt, especially in case of bacterial infection [1, 10]. Normal ventricular volume on admission (56%) carried a notable risk (8%) of latent shunt [1]. Shunt failures, particularly infection and occlusion, requiring repeated revisions, are still frequent after decades of development [25].

Joona Tervonen and Hadie Adams are first equal authorship

This article is part of the Topical Collection on Vascular Neurosurgery - Aneurysm

Joona Tervonen
joona.tervonen@kuh.fi; joonat@uef.fi

1 Department of Neurosurgery, Neurosurgery of KUH NeuroCenter, Kuopio University Hospital, Kuopio, Finland

2 Faculty of Health Sciences, School of Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
Valveless shunts were suggested to reduce occlusion [2]. Adjustable valves have reduced overdrainage and the need for surgical revision [28]. Concerning shunted aSAH survivors, we found few long-term follow-up studies on shunt revisions [3, 27, 30].

A total of 2191 consecutive aSAH patients were admitted to the Kuopio University Hospital from a defined population (I/1990 to VI/2018). The timelines of the 349 patients with a ventriculoperitoneal shunt were analyzed until death or June 2019. The focus was the 101 patients with an adjustable valve (2012–2018), as compared to the 232 patients with a fixed pressure valve (1990–2011) and the 16 patients with a valveless shunt (2010–2013). The aim was to identify risk factors for the first shunt revision.

Methods

Literature review

PubMed was searched for English articles on humans published between January 2000 and November 2019 using the following terms: [(subarachnoid hemorrhage) OR SAH OR aSAH) AND (shunt* OR shunted OR shunting) AND (revision* OR complication* OR obstruction* OR infection*)]. We searched for the original articles on the aSAH patient cohorts that studied the shunted patients and the revisions of their shunts. Table 1 summarizes the cohorts regarded as relevant for the present study.

Catchment population of Kuopio University Hospital (KUH)

KUH, one of the five University Hospitals in Finland, is an academic, non-profit, publicly funded tertiary center, which has solely provided full-time acute and elective neurosurgical services for the defined KUH catchment population of approximately 850,000 in Eastern Finland. The KUH area contains four Central Hospitals, each with 24/7 neuroacutology, CT services, and intensive care [17]. During the study period from 1990 to 2018, all cases of SAH (CT and spinal tap) were acutely transferred to KUH for neurointensive care, neuroradiology (4-vessel angiography and/or CT angiography), and neurosurgery [17]. Neurointensive care was provided virtually regardless of the age or condition on admission, including H&H 4–5 patients. A dedicated team

Table 1 Characteristics of previous relevant cohorts on shunt revisions in patients with shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage (aSAH)

| Authors                  | Total aSAH patients (years) | Shunted patients (%) | First revisions (%) | Follow-up time | Shunt complications (%) | Risk factors for revision                                      |
|--------------------------|-----------------------------|----------------------|---------------------|---------------|------------------------|---------------------------------------------------------------|
| O’Kelly et al., 200920   | 3120 (1995–2004)            | 585 (19%)            | 173 (30%)           | Mean 4.25 years| N/A                    | Posterior circulation sIA Endovascular treatment              |
| Chalouhi et al., 201419  | N/A (2005–2010)             | 523 (N/A)            | 66 (13%)            | Mean 2.0 years| Infection (n=33; 6.3%)  | Clipping of sIA and higher H&H for infection                 |
|                         |                             |                      |                     |               | Ventricular catheter or valve failure (n=32; 6.1%) | Clipping of sIA for proximal ventriculoperitoneal shunt revision |
|                         |                             |                      |                     |               | ICH (n=1; 0.2%)       |                                                               |
| Paisan et al., 201821   | 888 (2000–2015)             | 116 (13%)            | 21 (18%)            | Mean 1.5 years| Infection (n=8; 6.9%)  | WFNS ≥ III                                                   |
|                         |                             |                      |                     |               | Valve failure (n=11; 9.5%) | Posterior circulation sIA                                    |
|                         |                             |                      |                     |               |                         | Vasospasm                                                   |
| Tervonen et al., 2021   | 2191 (1990–2018)            | 349 (16%)            | 232 fixed pressure  | Median 8.3 years| Infection (n=31; 8.9%)  | Valveless shunt; HR = 2.94                                   |
|                         |                             |                      | valves 16 valveless| (IQR 3.6–15 years)|                         |                                                               |
|                         |                             |                      | shunts 101 adjustable|               |                         |                                                               |
|                         |                             |                      | valves            |               |                         |                                                               |

Abbreviations: N/A, not applicable; WFNS, World Federation of Neurological Surgeons SAH grade (I–V); H&H, Hunt and Hess grade (I–V); sIA, saccular intracranial aneurysm; EVD, extraventricular drainage; ICH, intracerebral hemorrhage
of neurointensivists, neurosurgeons, and neuroradiologists coordinated the aSAH treatment. KUH Neurovascular Group evacuated significant ICHs with immediate microsurgery. The KUH aSAH protocol followed international recommendations in detail [7, 9, 31, 34], including routine extraventricular drainage (EVD) and parenchymal ICP monitoring, decompressive craniectomy (DC) when needed, and intraarterial nimodipine in delayed brain ischemia.

**Kuopio Intracranial Aneurysm (IA) Patient and Family Database**

The database, prospective since 1995, contains all cases of unruptured and ruptured IAs admitted to KUH since 1980. A dedicated, full-time nurse administrates the database; interviews all new IA patients, including their family history; and arranges the follow-ups. The clinical data, including prescribed medicines, hospital diagnosis, and causes of death, have been fused from the national registries, using the Finnish personal codes. We have previously characterized the aSAH patients, e.g., diabetes mellitus [24], hypertension [23], for the 14-day mortality and organ donation [17], 12-month mortality [15], shunt-dependent hydrocephalus [1], epilepsy [14], psychosis [13], and long-term excess mortality [16]. Three 1-degree relatives with a diagnosed sIA disease form an sIA family.

**Study population**

A total of 2191 consecutive adult (> 18 years) aSAH patients were acutely admitted to the KUH Neurointensive Care from 1990 to 2018 from a defined population (Fig. 1). Their clinical lifelines have been reconstructed from their clinical data in the Kuopio database and from the national clinical registries until death or the last follow-up [13, 29]. The final study population consisted 349 aSAH patients who received their first ventriculoperitoneal shunt in a median time of 24 days (IQR 9–60 days) after aSAH (Fig. 1, Table 2).

**Variables and clinical data retrieval sources**

The characteristics and variables of the patients (n = 349) and the primary shunts are described in Table 2. The clinical data was retrieved and reviewed from the following sources: Kuopio IA Database, with data fusion from the national registries; KUH case reports, referrals from the four Central Hospitals, and neurosurgical operative reports on shunt installations and revisions (manually 1990–2004; digitally until June 2019); neuroimaging (manually 1990–2002; digitally until June 2019); monitoring data before, during, and after all shunt installations and revisions; and laboratory and bacteriology data. The follow-up time ended at death (n = 120) or June 2019. No patients were lost to follow-up.

![Fig. 1 Timelines of three shunt types in 349 patients with hydrocephalus after aneurysmal subarachnoid hemorrhage (aSAH). A total of 2191 consecutive patients with aSAH from ruptured saccular intracranial aneurysm (sIA) were acutely admitted to the Neurointensive Care at the Kuopio University Hospital (KUH) between 1990 and 2018 from its defined Eastern Finnish catchment population. The study cohort consists of 349 consecutive aSAH patients with a primary ventriculoperitoneal shunt inserted for post-aSAH hydrocephalus. The annual numbers of the primary shunt insertions (n = 349) and their first revisions (n = 111) for either malfunction (n = 80) or shunt infection (n = 31) are indicated. Altogether, 232 fixed pressure shunt valves were primarily inserted from 1990 to 2011, and thereafter, only adjustable shunt valves (n = 101) were primarily used. The short period when most of the valveless shunts (n = 16) were inserted is indicated.](image)
Shunt surgery and follow-up for shunt complications

In the KUH catchment population, all adult shunt installations and revisions have been performed by KUH Neurosurgery. The shunted patients have been followed by the KUH Neurosurgery and Neurology Departments of the four Central Hospitals. During the study period since 1990, all Hospitals have had 24/7 CT services. Since 2010, adjustable valves have been reset also in the Central Hospitals. KUH Neurosurgery have treated all shunt complications, e.g., occlusions, infections, intracranial hematomas, overdrainages (clinical and/or radiological signs leading to valve adjustment or shunt revision), and subdural effusions.

Types of shunt valves used in 349 aSAH patients

During the recruitment period from 1990 to 2018, three types of valves were used (Table 2, Fig. 1). The adjustable valves without anti-siphon device enabled us to insert shunts earlier thus reducing the time of EVD.

1. Fixed pressure valves (n = 232):
   - Exclusively from 1990 to 2009 (n = 198); occasionally from 2010 to 2017 (n = 34)
   - > 5 mmHg opening pressure (n = 196)
   - 0–5 mmHg opening pressure (n = 36)

2. Adjustable valves (n = 101):

Table 2 The study population of 349 consecutive aSAH patients who received their first ventriculoperitoneal shunt with three different valve types after aSAH. They had been acutely admitted to the Neurointensive Care of Kuopio University Hospital from its Eastern Finnish catchment population from 1990 to 2018.

|                        | Adjustable valve 2012–2018 n = 101 | Valveless shunt 2010–2013 n = 16 | Fixed pressure valve 1990–2011 n = 232 |
|------------------------|-----------------------------------|----------------------------------|----------------------------------------|
| Females                | 69 (62%)                          | 12 (75%)                         | 130 (56%)                              |
| Member of sIA family   | 1 (1%)²                           | 0                                | 24 (10%)²                              |
| Median age at aSAH (years, IQR) | 59 (50–68)                        | 56 (47–63)                       | 58 (47–66)                             |
| Site of ruptured sIA   |                                   |                                  |                                        |
| Internal carotid artery | 23 (23%)                          | 7 (44%)                          | 44 (19%)                               |
| Anterior carotid artery | 42 (42%)                          | 5 (31%)                          | 108 (47%)                              |
| Middle cerebral artery | 21 (21%)                          | 2 (13%)                          | 43 (19%)                               |
| Vertebrobasilar artery | 15 (15%)                          | 2 (13%)                          | 37 (16%)                               |
| Median size of ruptured sIA (mm, IQR) | 6 (4–9)²                          | 6 (4–9)                          | 7 (5–10)²                              |
| Multiple sIAs (> 2)    | 22 (22%)                          | 6 (38%)                          | 71 (31%)                               |
| Hunt and Hess grade on admission |                               |                                  |                                        |
| I                      | 14 (14%)                          | 1 (6%)                           | 21 (9%)                                |
| II                     | 22 (22%)                          | 3 (19%)                          | 56 (24%)                               |
| III                    | 23 (23%)                          | 2 (13%)                          | 88 (38%)                               |
| IV                     | 33 (33%)                          | 9 (56%)                          | 55 (24%)                               |
| V                      | 9 (9%)                            | 1 (6%)                           | 12 (5%)                                |
| Intracerebral hemorrhage | 27 (27%)                          | 4 (25%)                          | 59 (25%)                               |
| Intraventricular hemorrhage | 61 (61%)²                         | 16 (100%)³                       | 102 (44%)²                              |
| Extraventricular drainage | 82 (82%)²                         | 16 (100%)³                       | 156 (67%)³                              |
| Meningitis prior shunt | 12 (12%)                          | 3 (19%)                          | 46 (20%)                               |
| Median days to first shunt (days, IQR) | 7 (5–16)                          | 10 (8–14)                        | 38 (21–90)                             |
| Antibiotic-impregnated shunt | 65 (65%)²                         | 16 (100%)³                       | 20 (9%)³                               |
| Silver-impregnated shunt* | 21 (21%)                          | n.r                             | 0 (0%)                                 |
| First revision         | 25 (25%)                          | 11 (69%)                         | 75 (32%)                               |
| Median time to first revision (days) | 7 (4–26)                          | 17 (9–104)                       | 48 (7–181)                             |
| Two or more revisions per patient | 12 (12%)                          | 5 (31%)                          | 39 (17%)                               |
| Median revision-free time after shunt (months) | 47 (25–73)                        | 72 (9–92)                        | 146 (92–232)                           |
| Deaths during follow-up | 15 (15%)                          | 4 (25%)                          | 105 (45%)                              |

Abbreviations: IQR, interquartile range; sIA, saccular intracranial aneurysm; aSAH, subarachnoid hemorrhage from ruptured sIA. *The proximal catheter silver-impregnated, the distal catheter antibiotic-impregnated

The superscript indicates the statistical significance (Kruskal–Wallis, p < 0.05) as follows: 1, adjustable vs. valveless; 2, adjustable vs. fixed; 3, valveless vs. fixed.

2706 Acta Neurochirurgica (2021) 163:2703–2714
Used since 2010 and the main valve type since 2012. Medtronic Strata NSC without an anti-siphon device (n=86) or Medtronic Strata II (n=15). Valve without anti-siphon device was used to reduce the risk for obstruction due to blood in CSF.

Control head CT (n=97) in a median of 3 days (IQR 2–6), MRI (n=3), or skull x-ray (n=1) to verify the ventricular catheter position after the shunt installation.

3. Valveless primary shunts in the study were Codman Uni-Shunts (n=16); these were inserted between 2010 and 2013.

Antibiotic prophylaxis (cefuroxime) was routinely administered i.v. (i) during the EVD and shunt installations (1.5 g) and (ii) administered i.v. 1.5 g three times a day during the EVD period.

Statistical analysis

Continuous variables were reported as medians and interquartile ranges (IQR). Frequencies and percentages were used with the categorical and the dichotomous variables. The association of the continuous variables on the first shunt revision was analyzed with the Mann–Whitney U test or the Kruskal–Wallis test. Categorical variables were evaluated by the $\chi^2$ test. The Cox regression analysis was used to identify the independent risk factors for the first shunt revision. Statistical analysis was performed using SPSS version 25.0 (SPSS, Inc., Chicago, IL). The differences were statistically significant if the p-value was <0.05.

Ethical approvals

The study was approved by the Ethical Committee of the Kuopio University Hospital. This was a retrospective database study including only the patients already treated in KUH for aSAH. The need for additional consent for this registry study was waived by the Ethics Committee of KUH. The data integration from the national registries was performed with the approval of the Ministry of Social Affairs and Health of Finland and the National Institute for Health and Welfare.

Results

The study population consisted of 349 aSAH patients who received their first ventriculoperitoneal shunt from 1990 to 2018 with three almost consecutive valve types after aSAH (Fig. 1, Table 2). Of the 349 patients, 111 (32%) underwent the first shunt revision in median of 23 days (IQR 6–111) until death (n=124) or June 2019, a total of 2513 follow-up years and a median of 8.3 years (Fig. 2).

Overall risk of shunt revision

The risk for the first revision was equal for the 101 adjustable valve shunts and the 196 fixed medium-pressure valve shunts but significantly lower (p=0.01) than for the 16 valveless shunts (Table 2, Fig. 2). In multivariate Cox regression analysis, the valveless shunt was the only independent risk factor (HR 2.9), with age group ≤57 years, EVD, and fixed low-pressure valve showing no significance (Table 3). Hunt and Hess grade, antibiotic-impregnated catheters, ICH, and IVH were tested but did not have statistical significance in the multivariate analysis.

Adjustable valves (n=101; 2012–2018)

Of the 349 shunted patients, 101 had an adjustable valve (Table 2, Fig. 3). Figure 4 presents a representative CT slice of each patient before the shunt insertion, with a special emphasis on the intraventricular blood amount. The puncture sites were frontal (n=94) or occipital (n=7).

Antibiotic-impregnated shunt was used in 65 patients and silver-impregnated ventricular catheter with antibiotic-impregnated distal catheter in 21 patients (Table 4). The initial valve settings were either 1.5 T (n=78), 1.0 T (n=19), 0.5 T (n=2), or 2.0 T (n=2). One or more adjustments were required in 32 (32%) of the 101 patients, due to clinical overdrainage in 17 (17%) in median of 71 days (IQR 0.6–269).
6–129) and clinical underdrainage in 15 (15%) in a median of 4 days (IQR 3–14).

Of the 101 patients, 82 (81%) had EVD and 19 (19%) had not (Fig. 3). The median time to shunt insertion was 7 days (IQR 5–11) with EVD (acute hydrocephalus) and 34 days (IQR 14–48) without EVD (latent hydrocephalus). The median follow-up time since shunt insertion, until death (n = 15) or June 2019, was 47 months (IQR 25–66).

No shunt revision was required in 76 (75%) of the 101 patients, until death (n = 10) or June 2019, a median revision-free time of 47 months. Of these 76 patients though, 23 (30%) required adjustments of the valve settings, at least once. In overall, 53 (52%) of the 101 patients, with a median time of 8 days to shunt insertion, did not require any shunt revisions or adjustments (Fig. 3).

Shunt revision was required in 25 (25%) of the 101 patients, until death (n = 5) or June 2019, in a median time of 7 days since shunt insertion (Table 4, Fig. 3). The cumulative rate for the first revision was 14% at 1 month and 23% at 1 year (Fig. 2). Of the 25 patients with shunt revision, nine had previous valve adjustments. In overall, multiple (two or more) revisions were required in 12 (48%) of the 25 revised patients.

Shunt infection (n = 11) was the most common cause for shunt revision, in a median of 5 days (Table 4, Fig. 3). All 11 patients had EVD and i.v. cefuroxime prophylaxis since

---

**Table 3 Univariate and multivariate Cox regression analyses for shunt revision risk**

| Factor                      | Patients (n = 349) | Hazard ratio | Univariate 95% CI | p-value | Hazard ratio | Multivariate 95% CI | p-value |
|-----------------------------|--------------------|--------------|-------------------|---------|--------------|--------------------|---------|
| Age > 57 years              | 184 (53%)          | 1.00         | Ref               | 1.00    | Ref          | 1.00               | Ref     |
| Age ≤ 57 years              | 165 (47%)          | 1.44         | 0.97–2.10         | 0.059   | 1.34         | 0.92–1.97          | 0.131   |
| No EVD                      | 95 (27%)           | 1.00         | Ref               | 1.00    | Ref          |                   |         |
| EVD                         | 254 (73%)          | 1.57         | 0.99–2.48         | 0.055   | 1.37         | 0.85–2.21          | 0.198   |
| Programmable valve          | 101 (29%)          | 1.00         | Ref               | 1.00    | Ref          |                   |         |
| Valveless shunt             | 16 (5%)            | 3.19         | 1.53–6.66         | 0.002*  | 2.94         | 1.40–6.15          | 0.004*  |
| Fixed pressure valve 0–5 mmHg | 36 (10%)          | 1.62         | 0.84–3.12         | 0.149   | 1.61         | 0.84–3.10          | 0.167   |
| Fixed pressure valve > 5 mmHg | 196 (56%)         | 1.06         | 0.66–1.70         | 0.818   | 1.12         | 0.69–1.81          | 0.719   |

Abbreviations: EVD, extraventricular drainage; Ref, reference in logistic regression analysis

*Statistically significant p-values < 0.05
the shunt installation. Ten patients had clinical meningitis, including decreased CSF glucose, and one had a wound infection. However, bacterial cultures remained negative, except in two cases (Staphylococcus warneri and Staphylococcus aureus) considered possible contaminations. The PCR testing of CSF samples was not performed. The infections somewhat clustered in the early shunts (Fig. 3).

Valve occlusion (n = 8) was the second most common reason for shunt revision, in a median of 12 days (Table 4, Fig. 3). The 15 shunts with the anti-siphon device were installed in a median of 39 days (IQR 8–220), and only one of them occluded. The 86 shunts without the anti-siphon device were installed much earlier (see Methods), in a median of 7 days (IQR 5–11), and seven of them occluded.

Valveless shunts (n = 16; 2010–2013)

Of the 349 shunted patients, 16 (4.6%) had a valveless shunt in a median of 10 days after aSAH (Table 2, Table 4, Fig. 1). All 16 patients had EVD. The median follow-up time since shunt insertion, until death (n = 4) or June 2019, was 90 months (19–106).

No shunt revision was required in five (31%) patients, until death (n = 3) or June 2019, a median revision-free time of 72 months. Shunt revision was required in 11 (69%) patients, until death (n = 1) or June 2019, in a median of 17 days (Table 4, Fig. 2). The causes of revision were shunt overdrainage (n = 5), shunt infection (n = 4), and ventricular catheter occlusion (n = 2) (Table 4). In overall, multiple revisions were required in 5 (45%) of the 11 revised patients.

Fixed pressure valves (n = 232; 1990–2011)

Of the 349 shunted patients, 232 (66%) had a fixed pressure valve, 36 with a low-pressure valve (0–5 mmHg), and 196 with a medium-pressure valve (>5 mmHg). Of the 232 patients, 156 (67%) had EVD and 76 (33%) had not. The median time to shunt insertion was 35 days (IQR 16–86) with EVD (acute hydrocephalus) and 48 days (IQR 24–100) without EVD (latent hydrocephalus). The median follow-up time since shunt insertion, until death (n = 105) or June 2019, was 133 months (91–227).

No shunt revision was required in 157 (68%) patients, until death (n = 72) or June 2019, a median revision-free time of 146 months (Table 2). Shunt revision was required in 75 (32%) patients, until death (n = 33) or June 2019, in a median of 48 days (Table 2, Fig. 2). The two most common causes of revision were valve occlusion (n = 27) and shunt infection (n = 16), reversal as compared to adjustable valves (Table 4). In overall, multiple revisions were required in 39 (52%) of the 75 revised patients.

Risk of revision with adjustable valve, fixed pressure valve, and valveless shunts

As Table 3 and Fig. 2 indicate, the risk for the first revision was equal for the 101 adjustable valve shunts and the 196 fixed medium-pressure valve shunts but significantly lower (p = 0.01) than for the 16 valveless shunts.

Discussion

In our basic cohort of 2191 consecutive aSAH patients from a defined population (1990–2018), a total of 349 (17%) required a permanent ventriculoperitoneal shunt due to acute or latent hydrocephalus. In two previous large cohorts, the shunt dependency was 13% and 19% (Table 1) in 888 and 3120 aSAH patients, respectively [27, 30]. Shunt failures in hydrocephalus of various causes, including aSAH, which may require repeated revisions, are frequent after 40 decades of development [25].

Shunt failures may be (i) mechanical (catheter disinsertion; catheter disconnection; exposure to skin), (ii) biological (meningitis; infection of the shunt; occlusion of catheters or valves), or (iii) hydrodynamic (underdrainage; overdrainage). We found few large-term follow-up studies on the shunt revisions in post-aSAH hydrocephalus [3, 27, 30].

In the present study of 349 shunted patients, the clinical date point timelines, reconstructed with the personal identity codes from the Finnish nationwide clinical registries, were analyzed until death (n = 124) or June 2019 with none lost to follow-up. A total of 111 (32%) patients underwent at least one shunt revision. In multivariate analysis, no other independent risk factors for the shunt revision than the use of valveless shunt were found. The focus was the 101 patients with an adjustable valve (2012–2018), as compared to the 232 patients with a fixed pressure valve (1990–2011) and the 16 patients with a valveless shunt (2010–2013) (Fig. 1).

In the 101 aSAH patients with an adjustable valve, the median time from the admission to the shunt was 7 days (Figs. 3 and 4). No shunt revision was required in 75%, a median revision-free time of 47 months. In 32 patients, the valve settings had to be adjusted after the shunt, and nine of them required a surgical shunt revision. In overall, shunt revision was required in 25% in a median of 7 days. The most common causes were shunt infection (11%) in a median of 5 days, in spite of intraoperative cefuroxime prophylaxis, and shunt occlusion (8%) in a median of 12 days. In the historic fixed pressure valve group (Fig. 1), the shunts were installed (median 38 days) and revised (median 48 days) significantly later, at an almost equal rate though (Fig. 2). In two previous aSAH cohorts, the adjustable valve shunts were less often revised as compared to the fixed pressure valve shunts: 7% and 9% vs. 22% and 30%, respectively [22, 28].
The adjustable valves, in our hands without the anti-siphon device, brought an important paradigm shift in our service as compared to the period of fixed pressure valves. Shunt valves without anti-siphon device enabled us to install shunts earlier to minimize the risk of occlusion and to reduce the time of EVD. Early shunt excludes the possibility to...
use EVD in maintaining an adequate CPP in case of severe vasospasm. However, early shunt was considered as soon as ICP monitoring was not required due to the decreased level of consciousness, but patients were still requiring CSF drainage. Early shunt can also shorten the neurointensive care period and can lead to earlier mobilization. Prolonged EVD or spinal drainage are risk factors for meningitis, even with antibiotic prophylaxis and use of antibiotic-impregnated catheters [10]. We can speculate that due to the use of antibiotic-impregnated catheters, the shunt infection rate was not increased despite of earlier shunt insertion. Two previous studies also supported early conversion of EVD into a ventriculoperitoneal shunt [18, 32]. Finally, adjustable valve shunts resolved the problems of overdrainage and underdrainage, previously requiring surgical revisions. This tallies with a recent study comparing 173 fixed pressure valves and 16 adjustable valves [6].

In our study, 16 primary valveless shunts were inserted in a brief 4-year period (Fig. 1), with the idea that shunting could take place at an earlier phase and with more blood in the CSF. However, the valveless shunts in our hands proved unsatisfactory: as many as 11 (69%) required at least one revision, five (31%) of them for overdrainage (Fig. 2). In contrast, in the Danish population-based cohort of 214 post-hemorrhagic hydrocephalus patients, including 161 SAH patients, there was no significant difference in the revision rates between the 137 valveless (26%) and 77 valve-regulated (29%) ventriculoperitoneal shunts [2]. Instead, the rate of overdrainage was significantly higher with the valveless shunts: 40% vs. 9%. In our overall series, the rates of overdrainage were 1%, 4%, and 31% for the 101 adjustable valve, 232 fixed pressure valve, and 16 valveless ventriculoperitoneal shunts, respectively. Our findings emphasize the need for clinical trials and prospective quality registries when implementing new innovations in neurosurgery.

The strengths of the present study are derived from the free tax-paid Finnish health care system. The five university hospitals of Finland have their own catchment areas which supports disease cohorts with minimal selection and long-term follow-ups with almost none dropped. Using the Finnish identity codes, all contacts to the healthcare system are automatically archived in the national clinical registries. Our follow-up was considerably longer as compared to previous studies (Table 1).

All shunt insertions and revisions were performed by the KUH neurosurgeons. There are also limitations. Our study is retrospective, although the database prospectively collected all aSAH patients through the study period. Furthermore, the detailed neurointensive care monitoring data, digitally available in the Finnish nationwide database [31], was not utilized here. Such data would be important for more detailed prediction of shunt occlusions, infections, and revisions in post-aSAH hydrocephalus.

The mechanisms, such as neuroinflammation, behind acute, latent, and chronic post-aSAH hydrocephalus are not fully understood, e.g., possible alterations in ependymal cells, ciliary beat, arachnoid villi, CSF production and resorption, or glymphatic circulation [11, 20]. Considering neuroinflammation, the use of dexamethasone after aSAH has been associated with the reduction in unfavorable outcome and the incidence of hydrocephalus [5, 26, 33]. The impact of dexamethasone, or any other modulator of inflammation, on the revision rates in shunted aSAH has not been established. Individual factors, including advanced age, concomitant diseases, and long neurointensive care, may affect the individual predisposition or resilience to shunt occlusions or infections — and might be modifiable.

Risk factors of shunt occlusion or shunt infection are difficult to define. There is no standard diagnosis for shunt infection, and different guidelines are used [37]. Negative CSF or catheter culture does not totally rule out shunt infection, especially under antibiotic prophylaxis, such as cefuroxime during our early conversions of EVD to shunts. Furthermore, asymptomatic infection may cause shunt occlusion. For further research, it is important to use PCR or sequencing of CSF, catheters, and valve contents to identify the causative pathogen or pathogens in all cases of occluded or infected shunt material.

Long-term outcome and quality of life of shunted aSAH survivors require further research. Risk factors of repeated revisions and possible methods to prevent them should be investigated. In our study, 12 (12%) of the 101 adjustable valve shunt patients and 39 (17%) of the 232 fixed pressure valves underwent two or more revisions. Among the 585 patients with a ventriculoperitoneal shunt for post-aSAH hydrocephalus, 74 (13%) underwent two or more revisions (32 at least three; 21 at least four) [27]. O’Kelly et al. [27] were unable to glean risk factors for the multiple shunt revisions. Finally, it is not known whether shunt-dependent hydrocephalus after aSAH is an independently dementing brain condition, apart from brain injuries at the acute and subacute phase [4].
Conclusions

Our analysis of 349 patients with a ventriculoperitoneal shunt for hydrocephalus due to aneurysmal subarachnoid hemorrhage (aSAH) suggests the following:

1. The protocol to shunt evolved over time to favor earlier shunt instead of weaning.
2. Adjustable valve shunts, in our hands without the anti-siphon device, can be installed at an early phase after aSAH with a modest risk (25%) of shunt revision.
3. Valveless shunts are not recommendable due to significantly higher risk of revision as compared to shunts with adjustable opening pressure.

Table 4 The study cohort of 349 consecutive aneurysmal subarachnoid hemorrhage (aSAH) patients with a primary ventriculoperitoneal shunt due to post-aSAH hydrocephalus from 1990 to 2018

|                        | Adjustable valves 2012–2018 n = 101 | Valveless shunts 2010–2013 n = 16 | Fixed pressure shunts 1990–2011 n = 232 |
|------------------------|-------------------------------------|-----------------------------------|----------------------------------------|
| Median time to shunt (days) | 7 (5–16)2 | 10 (8–14)3 | 38 (21–90)2,3 |
| Median follow-up after shunt (months) | 47 (25–66)2 | 90 (19–106)3 | 133 (91–227)2,3 |
| First revision | 25 (25%)1 | 11 (69%)1,3 | 75 (32%)3 |
| Median time to first revision (days) | 7 (4–26)2 | 17 (9–104) | 48 (7–181)2 |
| Shunt infection | 11 (11%) | 4 (25%) | 16 (7%) |
| Median time to revision (days) | 5 (3–17) | 12 (7–16) | 96 (12–513) |
| Antibiotic-impregnated shunt | 8/65 | 4/16 | 1/20 |
| Silver-impregnated shunt* | 3/21 | n.r | 0/0 |
| Normal catheter | 0/15 | n.r | 15/212 |
| Valve occlusion | 8 (8%) | n.r | 27 (12%) |
| Median time to revision (days) | 12 (5–59) | 0 | 33 (7–198) |
| Ventricular catheter malposition | 1 (1%) | 0 | 11 (5%) |
| Median time to revision (days) | 3 (3%) | 2 (13%) | 4 (2%) |
| Ventricular catheter occlusion | 4 (3–6) | 7 (5–13) | |
| Median time to revision (days) | 1 (1%) | 0 | 4 (2%) |
| Peritoneal catheter occlusion/malposition | 0 | 65 (7–113) | |
| Median time to revision (days) | 0 | 0 | 3 (1%) |
| Catheter disconnection | 0 | 0 | 3 (1%) |
| Shunt overdrainage leading to revision | 1 (1%)1 | 5 (31%)1,3 | 10 (4%)3 |
| Median time to revision (days) | 30 (17–104) | 90 (57–443) | |

*The proximal catheter silver-impregnated, the distal catheter antibiotic-impregnated

The superscript indicates the statistical significance (Kruskal–Wallis, p < 0.05) as follows: 1, adjustable vs. valveless; 2, adjustable vs. fixed; 3, valveless vs. fixed

Declarations

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Adams H, Ban VS, Leinonen V, Aoun SG, Huttunen J, Saavalainen T, Lindgren A, Frosen J, Fraunberg M, Koivisto T, Hernesniemi J, Welch BG, Jaaskelainen JE, Huttunen TJ (2016) Risk of Shunting After Aneurysmal Subarachnoid Hemorrhage: A Collaborative Study and Initiation of a Consortium. Stroke 47:2488–2496

Funding Open access funding provided by University of Eastern Finland (UEF) including Kuopio University Hospital. The study was funded by the Maire Taponen Foundation, Pro Humanitate Foundation, the Päivikki and Sakari Sohlberg Foundation, the Kuopio University Hospital, and the Academy of Finland.
2. Andreassen TH, Holst AV, Lilja A, Andresen M, Bartek J Jr, Eskesen V, Juhler M (2016) Valved or valveless ventriculoperitoneal shunting in the treatment of post-haemorrhagic hydrocephalus: a population-based consecutive cohort study. Acta Neurochirurgica (Wien) 158:261–70 discussion 270

3. Chalouhi N, Whiting A, Anderson EC, Witte S, Zanaty M, Tjoumakaris S, Gonzalez LF, Hasan D, Starke RM, Hann S, Gholbrial GM, Rosenwasser R, Jabbour P (2014) Comparison of techniques for ventriculoperitoneal shunting in 523 patients with subarachnoid hemorrhage. J Neurosurg 121:904–907

4. Corrao P, Henderson VW, Ording AG, Pedersen L, Horváth-Puho E, Sørensen HT (2017) Long-term risk of dementia among survivors of ischemic or hemorrhagic stroke. Stroke 48:180–186

5. Czorlich P, Sauvigny T, Ricklefs F, Abboud T, Nierhaus A, Vettorazzi E, Reuter DA, Regelsberger J, Westphal M, Schmidt NO (2017) Impact of dexamethasone in patients with aneurysmal subarachnoid haemorrhage. Eur J Neuro 24:645–651

6. Darkwah Oppong M, Droste L, Pierscianek D, Wrede KH, Rauschenbach L, Dammann P, Herten A, Forsting M, Sure U, Jabbbarli R (2020) Adjustable pressure valves for chronic hydrocephalus following subarachnoid hemorrhage: is it worthwhile? Clin Neurol Neurosurg 198:106133

7. de Oliveira Manoel AL, van der Jagt M, Amin-Hanjani S, Bambakis NC, Brophy GM, Balsara K, Claassen J, Connolly ES, Hofer SA, Hoh BL, Holloway RG, Kelly AG, Mayer SA, Nakaji P, Rabinstein AA, Vajkoczy P, Vergouwen MDI, Wroo H, Zimpfel GJ, Suarez JL, Unruptured Aneurysms and SAH - CDE Project Investigators (2019) Common data elements for unruptured intracranial aneurysms and aneurysmal subarachnoid hemorrhage: recommendations from the working group on hospital course and acute therapies-proposal of a multidisciplinary research group. Neurocrit Care 30:36–45

8. Diesing D, Wolf S, Sommerfeld J, Sarrafzadeh A, Vajkoczy P, Dengler NF (2018) A novel score to predict shunt dependency after aneurysmal subarachnoid hemorrhage. J Neurosurg 129:1273–1279

9. Diringer MN, Bleck TP, 3rd Claude Hemphill J, Menon D, Shutter L, Vespa P, Bruder N, Jr Connolly ES, Citerio G, Gress D, Hanggi D, Hoh BL, Lanzino G, Le Roux P, Rabinstein A, Schmutzhard E, Stocchetti N, Suarez JI, Treggiari M, Tseng MY, Vergouwen MD, Wolf S, Zimpfel G, Neurocritical Care Society (2011) Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care 15:211–240

10. Dorrestein KRIS, Brouwer MC, Jellemka K, van de Beek D (2020) Bacterial external ventricular catheter-associated infection. Expert Rev Anti Infect Ther 18:219–229

11. Farn MD, Zeineddine HA, Eliyak JK, Stadnik A, Jesselson M, McBee N, Lane K, Cao Y, Wu M, Zhang L, Thompson RE, John S, Ziai W, Hanley DF, Alper SL, Alper SL, Warf BC, Nedergaard M, Simard JM, Kahle KT (2020) Inflammation in acquired hydrocephalus: pathogenic mechanisms and therapeutic targets. Nat Rev Neurol 16:285–296

12. Korja M, Lehto H, Juvela S, Kaprio J (2016) Incidence of subarachnoid hemorrhage is decreasing together with decreasing smoking rates. Neurology 87:1118–1123

13. Lee JK, Seok YJ, Lee JH, Choi EH, Phi JH, Kim SK, Wang KC, Lee HJ (2012) Incidence and risk factors of ventriculoperitoneal shunt infections in children: a study of 333 consecutive shunts in 6 years. J Korean Med Sci 27:1563–1568

14. Lindgren AE, Kurki MI, Rihinen A, Koivist o T, Ronkainen A, Rinne J, Hernesniemi J, Eriksson JG, Jaaskelainen JE, von and zu Fraunberg M, Fraunberg M, Bendel S, Huttunen T, Kurki M, Hernesniemi J, Ronkainen A, Rinne J, Jaaskelainen JE, Koivist o T (2012) Risk factors for three phases of 12-month mortality in 1657 patients from a defined population after acute aneurysmal subarachnoid hemorrhage. World Neurosurg 78:631–639

15. Karimy JK, Reeves BC, Damisah E, Duy PQ, Antwi P, David W, Wang K, Schiff SJ, Limbrick DD Jr, Alper SL, Warf BC, Neder gaard M, Simard JM, Kahle KT (2020) Inflammation in acquired hydrocephalus: pathogenic mechanisms and therapeutic targets. Nat Rev Neurol 16:285–296

16. Lee JK, Seok YJ, Lee JH, Choi EH, Phi JH, Kim SK, Wang KC, Lee HJ (2012) Incidence and risk factors of ventriculoperitoneal shunt infections in children: a study of 333 consecutive shunts in 6 years. J Korean Med Sci 27:1563–1568

17. Lindgren AE, Kurki MI, Rihinen A, Koivist o T, Ronkainen A, Rinne J, Hernesniemi J, Eriksson JG, Jaaskelainen JE, von and zu Fraunberg M, Fraunberg M, Bendel S, Huttunen T, Kurki M, Hernesniemi J, Ronkainen A, Rinne J, Jaaskelainen JE, Koivist o T (2012) Risk factors for three phases of 12-month mortality in 1657 patients from a defined population after acute aneurysmal subarachnoid hemorrhage. World Neurosurg 78:631–639

18. Korja M, Lehto H, Juvela S, Kaprio J (2016) Incidence of subarachnoid hemorrhage is decreasing together with decreasing smoking rates. Neurology 87:1118–1123

19. Lee JK, Seok YJ, Lee JH, Choi EH, Phi JH, Kim SK, Wang KC, Lee HJ (2012) Incidence and risk factors of ventriculoperitoneal shunt infections in children: a study of 333 consecutive shunts in 6 years. J Korean Med Sci 27:1563–1568

20. Lindgren AE, Kurki MI, Rihinen A, Koivist o T, Ronkainen A, Rinne J, Hernesniemi J, Eriksson JG, Jaaskelainen JE, von and zu Fraunberg M, Fraunberg M, Bendel S, Huttunen T, Kurki M, Hernesniemi J, Ronkainen A, Rinne J, Jaaskelainen JE, Koivist o T (2012) Risk factors for three phases of 12-month mortality in 1657 patients from a defined population after acute aneurysmal subarachnoid hemorrhage. World Neurosurg 78:631–639

21. Karimy JK, Reeves BC, Damisah E, Duy PQ, Antwi P, David W, Wang K, Schiff SJ, Limbrick DD Jr, Alper SL, Warf BC, Neder gaard M, Simard JM, Kahle KT (2020) Inflammation in acquired hydrocephalus: pathogenic mechanisms and therapeutic targets. Nat Rev Neurol 16:285–296

22. Lee JK, Seok YJ, Lee JH, Choi EH, Phi JH, Kim SK, Wang KC, Lee HJ (2012) Incidence and risk factors of ventriculoperitoneal shunt infections in children: a study of 333 consecutive shunts in 6 years. J Korean Med Sci 27:1563–1568

23. Lindgren AE, Kurki MI, Rihinen A, Koivist o T, Ronkainen A, Rinne J, Hernesniemi J, Eriksson JG, Jaaskelainen JE, von and zu Fraunberg M, Fraunberg M, Bendel S, Huttunen T, Kurki M, Hernesniemi J, Ronkainen A, Rinne J, Jaaskelainen JE, Koivist o T (2012) Risk factors for three phases of 12-month mortality in 1657 patients from a defined population after acute aneurysmal subarachnoid hemorrhage. World Neurosurg 78:631–639

24. Korja M, Lehto H, Juvela S, Kaprio J (2016) Incidence of subarachnoid hemorrhage is decreasing together with decreasing smoking rates. Neurology 87:1118–1123

25. Lee JK, Seok YJ, Lee JH, Choi EH, Phi JH, Kim SK, Wang KC, Lee HJ (2012) Incidence and risk factors of ventriculoperitoneal shunt infections in children: a study of 333 consecutive shunts in 6 years. J Korean Med Sci 27:1563–1568

26. Lindgren AE, Kurki MI, Rihinen A, Koivist o T, Ronkainen A, Rinne J, Hernesniemi J, Eriksson JG, Jaaskelainen JE, von and zu Fraunberg M, Fraunberg M, Bendel S, Huttunen T, Kurki M, Hernesniemi J, Ronkainen A, Rinne J, Jaaskelainen JE, Koivist o T (2012) Risk factors for three phases of 12-month mortality in 1657 patients from a defined population after acute aneurysmal subarachnoid hemorrhage. World Neurosurg 78:631–639

27. O’Kelly CJ, Kulkarni AV, Austin PC, Urbach D, Wallace MC (2009) Shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage: incidence, predictors, and revision rates. Clinical article J Neurosurg 111:1029–1035
28. Orrego-González E, Enriquez-Marulanda A, Ascanio LC, Jordan N, Hanafy KA, Moore JM, Ogilvy CS, Thomas AJ (2020) A cohort comparison analysis of fixed pressure ventriculoperitoneal shunt valves with programmable valves for hydrocephalus following nontraumatic subarachnoid hemorrhage. Oper Neurosurg (Hagerstown) 18:374–383

29. Paavola JT, Vantti N, Junkkari A, Huttunen TJ, von Und Zu, Fraunberg M, Koivisto T, Kamarainen OP, Lang M, Meretoja A, Raikkonen K, Viinamaki H, Jaaskelainen JE, Huttunen J, Lindgren AE (2019) Antipsychotic use among 1144 patients after aneurysmal subarachnoid hemorrhage. Stroke 50:1711–1718

30. Paisan GM, Ding D, Starke RM, Crowley RW, Liu KC (2018) Shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage: predictors and long-term functional outcomes. Neurosurgery 83:393–402

31. Raj R, Bendel S, Reinikainen M, Hoppu S, Laitio R, Ala-Kokko T, Curtze S, Skrifvars MB (2018) Costs, outcome and cost-effectiveness of neurocritical care: a multi-center observational study. Crit Care 22:225–018–2151–5

32. Rammos S, Klopfenstein J, Augspurger L, Wang H, Wagenbach A, Poston J, Lanzino G (2008) Conversion of external ventricular drains to ventriculoperitoneal shunts after aneurysmal subarachnoid hemorrhage: effects of site and protein/red blood cell counts on shunt infection and malfunction. J Neurosurg 109:1001–1004

33. Schürkämper M, Medele R, Zausinger S, Schmid-Elsaesser R, Steiger HJ (2004) Dexamethasone in the treatment of subarachnoid hemorrhage revisited: a comparative analysis of the effect of the total dose on complications and outcome. J Clin Neurosci 11:20–24

34. Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G, Organization ES (2013) European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis 35:93–112

35. van Gijn J, Kerr RS, Rinkel GJ (2007) Subarachnoid haemorrhage. Lancet 369:306–318

36. Wilson CD, Safavi-Abbasi S, Sun H, Kalani MY, Zhao YD, Levitt MR, Hanel RA, Sauvageau E, Mapstone TB, Albuquerque FC, McDougall CG, Nakaji P, Spetzler RF (2017) Meta-analysis and systematic review of risk factors for shunt dependency after aneurysmal subarachnoid hemorrhage. J Neurosurg 126:586–595

37. Zervos T, Walters BC (2019) Diagnosis of ventricular shunt infection in children: a systematic review. World Neurosurg 129:34–44

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.